AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Business

Familiar Branded Drugs Top List of Medicines with Recent Price Hikes

Prescription drug costs have continued to rise, with more than 150 drug manufacturers raising their prices in January.

February 21, 2022

3 min read

Alex Keown

SKYRIZI is the new option for psoriatic arthritis.

Drug Development

AbbVie Leans on Skyrizi, Rinvoq as Humira Rides off the Patent Cliff

Humira will begin to lose exclusivity in 2023, and numerous biosimilar competitors are waiting to break in on the drug’s lucrative market.

February 2, 2022

4 min read

Mark Terry

Drug Development

AbbVie’s SKYRIZI Offers New Option for Psoriatic Arthritis Sufferers

The U.S. Food and Drug Administration has approved SKYRIZI (risankizumab-rzaa), AbbVie’s proposed treatment for adults diagnosed with active psoriatic arthritis (PsA).

January 24, 2022

2 min read

Vanessa Doctor, RN

Policy

Impostors! Crime in the Time of COVID-19 Targets Life Science Industry

While many of these scams targeted the public at large, scammers also turned their sights to those sources that would naturally be on the spot as the result of demand.

January 17, 2022

5 min read

Kaylei Whalen

Bio NC

BioSpace Launches 2022 Hotbed Maps to Highlight Thriving Life Sciences Clusters

As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.

January 17, 2022

6 min read

Heather McKenzie

Courtesy of Smith Collection/Gado/Getty Images

Drug Development

AbbVie’s Rinvoq Racks Up Expanded Win In Atopic Dermatitis

Expanded approval for Rinvoq was based on three Phase III studies that included more than 2,500 patients. The studies met all primary and secondary endpoints.

January 17, 2022

2 min read

Alex Keown

Drug Development

JPM Day 3: AbbVie Sees Bright Future Ahead, vTv, Gritstone and Achilles

Looking at long-term growth, Michael said that will be driven by numerous differentiated assets across each of Abbvie’s core areas.

January 13, 2022

4 min read

Alex Keown

Business

ONK Snags $21.5 Million for Natural Killer Cell Therapies

ONK announced an infusion of $21.5 million to propel their NK-powered programs towards IND-enabling studies.

January 6, 2022

2 min read

Kate Goodwin

Biotech Bay

Predicting the Life Sciences Investment Market in 2022

Mark Charest, Ph.D., of LifeSci Fund Management, said the J.P. Morgan Healthcare Conference will set the tone for biotech stock performance in 1H 2022.

January 5, 2022

5 min read

Heather McKenzie

JOBS